Overview

A Clinical Trial to Evaluate the Clinical Efficacy of Cyclosporine 0.1% (Ikervis®) for Moderate to Severe Dry Eye Patients. (IKE-03-SWITCHING)

Status:
Recruiting

Trial end date:
2022-01-01

Target enrollment:

Participant gender:

Summary

A clinical trial to evaluate the efficacy and safety of Cyclosporine 0.1% (Ikervis®) for moderate to severe dry eye patients who changed to Cyclosporine 0.1% eye drop(Ikervis®) due to lack of treatment effects of the previous Cyclosporine 0.05% eye drop.

Phase:

Phase 4

Details

Lead Sponsor:

Yonsei University

Treatments:

Cyclosporine
Cyclosporins
Ophthalmic Solutions